FMC 2015

The programme of the Frontiers in Medicinal Chemistry Symposium is now available!

Conferences > Archives > FMC 2015

Confirmed Speakers


Vorapaxar Discovery and Clinical Benefits
Dr Patrick ANDREDr Patrick ANDRE
(MERCK & CO., Kenilworth, United States)

Read more
Discovery and Development of Bedaquiline: A Rocky Road
Prof. Koen ANDRIESProf. Koen ANDRIES
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)

Read more
High Affinity Bicyclic Peptides: Application to Payloads in Oncology
Dr Gavin BENNETTDr Gavin BENNETT
(BICYCLE THERAPEUTICS , Cambridge, United Kingdom)

Read more
A Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety
Dr Claire BOUIX-PETERDr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France)

Read more
Panellist 2
Prof. Chas BOUNTRAProf. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
Structure-Based Design of Inhibitors of Factor XIa
Dr James CORTEDr James CORTE
(BRISTOL MYERS SQUIBB, Princeton, United States)

Read more
Sharing Compound Collections: UCB's First Experiences from the European Lead Factory
Dr Jeremy DAVISDr Jeremy DAVIS
(UCB, Slough, United Kingdom)

Read more
Science, Business & Innovation in Medicinal Chemistry
Prof. Iwan DE ESCHProf. Iwan DE ESCH
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Read more
Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD
Dr Chris DE SAVIDr Chris DE SAVI
(ASTRAZENECA R&D, Boston, United States)

Read more
Locally-acting ROCK Inhibitors for the Treatment of Eye Diseases
Dr Olivier DEFERTDr Olivier DEFERT
(AMAKEM, Diepenbeek, Belgium)

Read more
Revealing The Structural Basis for GPCR Drug Action through Atomic-Level Simulation
Prof. Ron DRORProf. Ron DROR
(STANFORD UNIVERSITY, Stanford, United States)

Read more
The Discovery Of A New Validated Target For Tuberculosis Via Phenotypic Screening
Ms Raquel FERNANDEZMs Raquel FERNANDEZ
(GLAXOSMITHKLINE, Tres Cantos, Spain)

Read more
Drug Target Residence Time: HSP90, a Model to Gain Insight into the Molecular Mechanism of Binding
Dr Matthias FRECHDr Matthias FRECH
(MERCK, Darmstadt, Germany)

Read more
Targeting Protein-Protein Interactions in the Heat Shock Protein 70 (Hsp70) Complex
Prof. Jason  GESTWICKIProf. Jason GESTWICKI
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

Read more
Kinetics in Drug discovery - A Case for the Adenosine Receptors
Mr Dong GUOMr Dong GUO
(LEIDEN UNIVERSITY, Leiden , The Netherlands)
The Discovery of Chemical Probes for Bromodomain Containing Proteins
Prize winner EFMC-YMCS 2014
Dr Duncan HAYDr Duncan HAY
(EVOTEC, Abingdon, United Kingdom)

Read more
Discovery & Optimisation of Novel Antagonists to the Human Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders: From Hit to Clinic
Dr Hamid HOVEYDADr Hamid HOVEYDA
(EUROSCREEN, Woluwe-Saint-Lambert, Belgium)

Read more
Novel JAK Inhibitors for Inhaled and Topical Delivery
Dr Peter JONESDr Peter JONES
(PFIZER, Cambridge, United States)

Read more
Discovering A Potent Allosteric Kinase Modulator Employing A Computational And Synthetic Toolbox
Mr Edwin KROONMr Edwin KROON
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

Read more
Towards 3rd Generation Antihistamines: Fact or Fiction?
Prof. Rob LEURSProf. Rob LEURS
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Read more
The Role of CXCR4 Modulators in Controlling HIV Entry, Stem Cell Mobilisation and Certain Types of Cancer
Prof. Dennis LIOTTAProf. Dennis LIOTTA
(EMORY UNIVERSITY, Atlanta, United States)

Read more
Discovery and Optimisation of Bioactive Macrocycles from DNA-Encoded Libraries
Dr Patrick MCENANEYDr Patrick MCENANEY
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)

Read more
Panellist 1
Prof. Christa MÜLLERProf. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

Read more
Privileged Structures Unlocking Therapeutic Target Families
Dr Gerhard MÜLLERDr Gerhard MÜLLER
(MERCACHEM, Martinsried, Germany)

Read more
Translating Medicinal Chemistry Research into Targeted Therapeutics. Building on Academic Knowledge
Prof. Roberto PELLICCIARIProf. Roberto PELLICCIARI
(UNIVERSITY OF PERUGIA, Corciano, Italy)

Read more
Sanford-Burnham’s Experience with the NIH’s Molecular Libraries Program
Dr Anthony PINKERTONDr Anthony PINKERTON
(SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, La Jolla, United States)

Read more
Targeting Factor XII in Thrombosis and Inflammation
Prof. Thomas  RENNEProf. Thomas RENNE
(KAROLINSKA INSTITUTET, Stockholm, Sweden)

Read more
Measuring The Dynamics Of Target Engagement Inside Cells Using Bret
Dr Matthew ROBERSDr Matthew ROBERS
(PROMEGA, Madison, United States)

Read more
Story of the Hsp27 Inhibitor Apatorsen
Dr Palma ROCCHIDr Palma ROCCHI
(MARSEILLE CANCEROLOGY RESEARCH CENTER, Marseille, France)

Read more
Exploring Macrocycles for Protein-protein Interaction Targets: the Discovery of Novel Bifunctional XIAP Antagonists
Dr Nick TERRETTDr Nick TERRETT
(ENSEMBLE THERAPEUTICS CORPORATION, Kriens, Switzerland)

Read more
Discovery of Highly Efficacious Potentiators for the Treatment of Cystic Fibrosis
Dr Steven VAN DER PLASDr Steven VAN DER PLAS
(GALAPAGOS, Mechelen, Belgium)

Read more
The Design of mGlu2 Negative Allosteric Modulators for the Treatment of Neuropsychiatric Disorders
Dr Michiel VAN GOOLDr Michiel VAN GOOL
(JANSSEN R&D, Toledo, Spain)

Read more
Regulated Necrosis: Disease Relevance and Therapeutic Opportunities
Prof. Peter VANDENABEELEProf. Peter VANDENABEELE
(UNIVERSITY OF GHENT, Ghent, Belgium)

Read more
Selective JAK1 Inhibitor for the Treatment of Autoimmune Diseases
Dr Michael L. VAZQUEZDr Michael L. VAZQUEZ
(PFIZER, Cambridge, United States)

Read more
Update on Hsp90 Inhibitors as Cancer Therapeutics
Dr Weiwen YINGDr Weiwen YING
(SYNTA PHARMACEUTICALS, Lexington, United States)

Read more

Jointly organised by

With the support of

Silver Sponsors

Bronze Sponsors

Premium Exhibitors

Media Partners

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys